posted on 2023-11-13, 17:10authored bySofia
G. Nikolopoulou, Beata Kalska, Anna Basa, Athina Papadopoulou, Eleni K. Efthimiadou
Cancer is one of the leading causes
of death worldwide. Conventional
therapies lack selectivity and suffer from toxicity and drug resistance,
leading to metastasis. To overcome these limitations, a new category
of nanomaterials exploiting the tumor characteristics has been developed
in cancer nanotherapeutics. Among them, pH, metabolism, and the disrupted
architecture of cells can be exploited for theranostic applications.
Such nanomaterials can be inorganic nanoparticles with silver ones
and gain high attention as diagnostic, therapeutic, and antibacterial
compounds. Silver has been linked with triggering the death of cancer
cells via DNA damage due to the production of reactive oxygen species
(ROS) during photodynamic therapy. Thus, improvement of biocompatibility,
modification with targeted agents, and drug conjugation promote the
use of silver nanoparticles. In this work, we managed to synthesize
hybrid Ag@SiO2 core–shell nanoparticles via a modified
sol–gel method by tackling the known etching of silver caused
by ammonia by employing different bases of the sol–gel reaction.
The bases used in the synthetic route were diethylamine (DEA) and
triethylamine (TEA) and were monitored with silver nanoparticles individually
from the absorbance peak of silver in the UV–vis region, showing
no etching of silver in contrast with ammonia, which is usually used
in the sol–gel method. Furthermore, we synthesized biocompatible
nanoparticles with anticancer and diagnostic properties toward breast
cancer cells and glioblastoma cells. The nanoparticles were characterized
both structurally and morphologically. Their biological evaluation
suggests minor toxicity toward healthy cells and red blood cells (RBCs).
Also, the diagnostic potential of the hybrid nanoparticles was exploited
by optical fluorescence microscopy. Therefore, we strongly suggest
the investigation of such nanostructures as a dual platform for the
diagnosis and therapy of cancer.